315,160 Shares in Bioventus Inc. $BVS Acquired by Meros Investment Management LP

Meros Investment Management LP bought a new position in Bioventus Inc. (NASDAQ:BVS) in the fourth quarter, Holdings Channel reports. The firm bought 315,160 shares of the company’s stock, valued at approximately $2,345,000.

A number of other institutional investors also recently bought and sold shares of BVS. Nantahala Capital Management LLC boosted its stake in Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock worth $34,959,000 after purchasing an additional 1,155,192 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in Bioventus in the 4th quarter worth approximately $2,886,000. Kent Lake PR LLC acquired a new stake in Bioventus in the 2nd quarter worth approximately $2,317,000. Kennedy Capital Management LLC boosted its stake in Bioventus by 219.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock worth $3,088,000 after purchasing an additional 317,157 shares in the last quarter. Finally, Hillsdale Investment Management Inc. acquired a new stake in Bioventus in the 4th quarter worth approximately $2,008,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $8.60 on Tuesday. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $11.25. The company has a 50 day simple moving average of $9.59 and a two-hundred day simple moving average of $8.65. The stock has a market cap of $718.44 million, a price-to-earnings ratio of 20.98, a PEG ratio of 1.10 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, analysts predict that Bioventus Inc. will post 0.77 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on BVS shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Craig Hallum lifted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. CJS Securities assumed coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective for the company. Finally, Barrington Research restated an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Bioventus has an average rating of “Buy” and a consensus price target of $14.00.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.